Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:19 AM
Ignite Modification Date:
2025-12-25 @ 12:19 AM
NCT ID:
NCT06750458
Brief Summary:
The aim of the study is to compare between the role of dapagliflozin versus dexamethasone in pre-operative management of non-diabetic glioma patients on levetiracetam as anti-seizure drug.
Detailed Description:
* This is a randomized, parallel, and controlled study, which will be conducted on pre-operative non-diabetic glioma patients on levetiracetam as anti-seizure drug. \* This study will be conducted pending registration at ClinicalTrials.gov.
* All patients will give their written informed consents.
* Data of patients will be confidential.
* Any unexpected risk will be reported to patients and Ethical Committee on time. \* Randomization will be carried out based on days on hospital admission.
Study:
NCT06750458
Study Brief:
Protocol Section:
NCT06750458